Related Experiment Videos
Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat
F Villani1, E Monti, F Piccinini
1Servizio di Fisiopatologia Cardiorespiratoria, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
Anticancer Research
|July 1, 1988
Summary
This study investigated doxorubicin-induced cardiotoxicity in rats. Trifluoperazine did not prevent the electrocardiographic and cardiac damage caused by doxorubicin treatment.
Area of Science:
- Pharmacology
- Toxicology
- Cardiovascular Research
Background:
- Doxorubicin (DXR) is a widely used chemotherapy agent.
- DXR is known to cause significant cardiotoxicity.
- Effective strategies to mitigate DXR-induced cardiotoxicity are needed.
Purpose of the Study:
- To evaluate the potential cardioprotective effects of trifluoperazine (TFP) against doxorubicin-induced cardiotoxicity.
- To assess the impact of TFP on electrocardiographic and morphological changes in the heart caused by DXR.
Main Methods:
- Sprague Dawley rats were administered doxorubicin (3 mg/kg i.v.) every third day for three doses.
- Trifluoperazine (0.2 or 2 mg/kg i.p.) was administered daily for 4 weeks, starting one day before DXR.
- Electrocardiographic (ECG) alterations (Qat and Sat prolongation) and left ventricular morphologic lesions were assessed.
Main Results:
- Doxorubicin induced significant ECG alterations, including Qat and Sat prolongation.
- DXR administration resulted in typical morphologic lesions in the left ventricle.
- Trifluoperazine treatment was ineffective in preventing the DXR-induced electrocardiographic and morphologic cardiac damage.
Conclusions:
- Trifluoperazine does not offer protection against acute and delayed cardiotoxicity induced by doxorubicin in this rat model.
- Further research is required to identify effective cardioprotective agents against doxorubicin chemotherapy.